8-K: Boston Scientific to Acquire Penumbra for $14.5 Billion

Boston Scientific Corporation will acquire Penumbra, Inc. in a cash and stock transaction valued at $374 per share, expanding its cardiovascular and neurovascular portfolios.

Summary

• Penumbra, Inc. has entered into a definitive merger agreement with Boston Scientific Corporation, where Penumbra will become a wholly owned subsidiary of Boston Scientific.
• The transaction values Penumbra at $374.00 per share, reflecting an enterprise value of approximately $14.5 billion.
• Penumbra shareholders can elect to receive either $374.00 in cash or 3.8721 shares of Boston Scientific common stock per Penumbra share.
• The total consideration will be paid approximately 73.26% in cash and 26.74% in Boston Scientific common stock, subject to proration.
• Outstanding Company Options and Accelerated RSUs will be converted into a mix of cash ($274.00 per share) and Boston Scientific stock (1.0353 shares per share), adjusted for exercise price and taxes.
• Other outstanding Company RSUs will be assumed by Boston Scientific and converted into restricted stock unit awards denominated in Boston Scientific shares.
• Boston Scientific expects to finance the approximately $11 billion cash portion of the transaction with a combination of cash on hand and new debt.
• The transaction is anticipated to be $0.06-$0.08 dilutive to Boston Scientific's adjusted earnings per share in the first full year post-acquisition, becoming neutral to slightly accretive in the second year and more accretive thereafter.
• Penumbra reported preliminary unaudited Q4 2025 revenue of $383.0 million to $384.8 million, representing 21.4% to 22.0% growth year-over-year.
• Full year 2025 preliminary unaudited revenue for Penumbra is $1,401.3 million to $1,403.1 million, a growth of 17.3% to 17.5% over 2024.
• Preliminary gross margin for Q4 2025 was 67.9% to 68.1%, and 67.1% for the full year 2025.
• Preliminary income from operations for Q4 2025 was $56.9 million to $60.4 million (operating margin 14.8% to 15.7%), and for full year 2025 was $186.9 million to $190.4 million (operating margin 13.3% to 13.6%).

Sentiment

Score: 8

Explanation: The filing announces a definitive merger agreement at a significant premium, coupled with strong preliminary financial results for the acquired company. While there's initial dilution for the acquirer, the strategic rationale and long-term accretion are positive. Risks are standard for M&A but manageable.

Positives

• Penumbra shareholders receive a significant premium at $374.00 per share, with the option for cash or Boston Scientific stock.
• The acquisition provides Penumbra's innovative technologies with expanded access to more patients and customers globally through Boston Scientific's established network.
• Penumbra reported strong preliminary financial results for Q4 and full year 2025, including revenue growth of 21.4%-22.0% and 17.3%-17.5% respectively.
• The transaction is expected to enhance Boston Scientific's revenue and margins over time, with Penumbra's proven offerings having a history of growth and innovation.
• Penumbra's CEO, Adam Elsesser, will join Boston Scientific's board of directors, indicating continuity and integration of leadership.

Negatives

• The transaction is expected to be dilutive to Boston Scientific's adjusted earnings per share by $0.06-$0.08 in the first full year following the acquisition.
• GAAP earnings per share for Boston Scientific are also expected to be dilutive in the first full year due to amortization expense and acquisition-related net charges.
• Penumbra's securities will be delisted from the NYSE and deregistered, ending its independent public trading status.

Risks

• Uncertainty regarding the completion of the proposed transaction on anticipated terms and timing, including obtaining stockholder and regulatory approvals.
• Potential for unforeseen liabilities, future capital expenditures, and impacts on revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies, expansion and growth of Penumbra's business.
• Failure to realize the anticipated benefits of the proposed transaction, including as a result of delays in completing the transaction or integrating the businesses of Penumbra and Boston Scientific.
• Risks related to Penumbra's ability to implement its business strategies post-acquisition.
• Impact of pricing trends on the combined entity.
• Potential litigation relating to the proposed transaction that could be instituted against Penumbra or its directors.
• Disruptions from the proposed transaction harming Penumbra's business, including current plans and operations.
• Challenges in retaining and hiring key personnel for Penumbra.
• Potential adverse reactions or changes to business relationships resulting from the announcement, pendency, or completion of the proposed transaction.
• Uncertainty as to the long-term value of Boston Scientific's common stock, which forms part of the merger consideration.
• Impact of legislative, regulatory, and economic developments affecting Penumbra's business.
• General economic and market developments and conditions.
• Evolving legal, regulatory, and tax regimes under which Penumbra operates.
• Potential business uncertainty, including changes to existing business relationships, during the pendency of the proposed transaction that could affect Penumbra's financial performance.
• Restrictions during the pendency of the proposed transaction that may impact Penumbra's ability to pursue certain business opportunities or strategic transactions.
• Unpredictability and severity of catastrophic events, including acts of terrorism or outbreak of war or hostilities.
• Failure to receive the approval of Penumbra's stockholders.

Future Outlook

The transaction is expected to be $0.06-$0.08 dilutive to Boston Scientific's adjusted earnings per share in the first full year following the close of the acquisition, becoming neutral to slightly accretive in the second year and more accretive thereafter. The impact to GAAP earnings per share is expected to be dilutive in the first full year, and less dilutive or increasingly accretive thereafter, due to amortization expense and acquisition-related net charges. Penumbra continues to advance its technologies with a multi-year research and development plan and ongoing clinical programs.

Management Comments

• Mike Mahoney, chairman and chief executive officer, Boston Scientific: "I'm thrilled to combine the talents and shared values of our teams including welcoming Penumbra's chairman and chief executive officer, Adam Elsesser, to our board of directors upon close. The addition of Penumbra can expand access for these novel technologies to more patients and customers around the world, further enhancing our revenue and margins over time with proven offerings that have a history of growth and innovation."
• Adam Elsesser, chairman and chief executive officer, Penumbra: "I am grateful for the amazing people who have contributed to this work and look forward to uniting our efforts and shared values as we come together with Boston Scientific."

Industry Context

This acquisition significantly expands Boston Scientific's cardiovascular portfolio and provides a scaled entry into the fast-growing mechanical thrombectomy and neurovascular segments. Penumbra, recognized as the world's leading thrombectomy company, brings differentiated devices for conditions like ischemic stroke, venous thromboembolism, and acute limb ischemia. The move addresses the increasing global prevalence of vascular diseases and aligns with Boston Scientific's strategy to offer high-performance solutions for complex medical conditions.

Management Changes

Corporate Governance

Legal Proceedings

• Potential litigation relating to the proposed transaction that could be instituted against Penumbra or its directors is identified as a risk.
• The Company will give Parent reasonable opportunity to participate in the defense of any Transaction Litigation and will consult on settlement.

Stakeholder Impact

• Shareholders of Penumbra will receive a cash and/or stock consideration for their shares, representing a premium.
• Employees of Penumbra will receive base salary/wage rates no less favorable, and incentive opportunities and benefits substantially comparable to those provided by Boston Scientific for one year post-merger.
• Customers and suppliers may experience changes in business relationships due to the acquisition, which is noted as a potential risk.
• Adam Elsesser, Penumbra's CEO, will join Boston Scientific's board, providing continuity and representation for Penumbra's legacy.

Next Steps

• Parent will file a registration statement on Form S-4, including a proxy statement/prospectus, with the SEC.
• Penumbra will mail the proxy statement/prospectus to its stockholders.
• Penumbra will convene a meeting of its stockholders to obtain the Company Stockholder Approval.
• The parties will seek required regulatory approvals and clearances under the HSR Act and other Antitrust Laws.
• Boston Scientific will seek approval for listing of its shares to be issued in the merger on the NYSE.
• Penumbra will cooperate to delist its shares from the NYSE and deregister them under the Exchange Act after the Effective Time.
• The transaction is expected to be completed in 2026.

Key Dates

Recommendation

The definitive merger agreement offers Penumbra shareholders $374.00 per share, a significant premium. For existing shareholders, holding the stock until the merger closes allows them to realize this value. For new investors, buying at or below the current market price (if it's below $374) could offer a small arbitrage opportunity, but the primary upside is capped at the offer price. Given the definitive nature of the agreement and the stated intention to close in 2026, the recommendation is 'hold' for existing shareholders to capture the deal value, or 'buy' if the market price is below the offer price, assuming the deal closes as expected.

Keywords

Merger, Acquisition, Thrombectomy, Neurovascular, Cardiovascular, Medical Devices, Boston Scientific, Penumbra, Healthcare, SEC Filing, 8-K, Financial Results